Cargando…

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regardin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neelapu, Sattva S, Adkins, Sherry, Ansell, Stephen M, Brody, Joshua, Cairo, Mitchell S, Friedberg, Jonathan W, Kline, Justin P, Levy, Ronald, Porter, David L, van Besien, Koen, Werner, Michael, Bishop, Michael R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Position Article and Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768967/ https://www.ncbi.nlm.nih.gov/pubmed/33361336 http://dx.doi.org/10.1136/jitc-2020-001235

Ejemplares similares

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
por: Maus, Marcela V, et al.
Publicado: (2020)

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
por: Boyiadzis, Michael M, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Greten, Tim F, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
por: Emens, Leisha A, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
por: Galsky, Matthew D, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
por: Kelly, Ronan J, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
por: Disis, Mary L, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
por: Silk, Ann W, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
por: Pavlick, Anna C, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
por: Govindan, Ramaswamy, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
por: Kluger, Harriet, et al.
Publicado: (2023)

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2020)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
por: Boyiadzis, Michael, et al.
Publicado: (2016)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
por: Rizvi, Naiyer, et al.
Publicado: (2023)

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit
por: Pai, Sara, et al.
Publicado: (2020)

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
por: Kluger, Harriet M., et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
por: Puzanov, I., et al.
Publicado: (2017)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
por: Rini, Brian I., et al.
Publicado: (2016)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
por: McNeel, Douglas G., et al.
Publicado: (2016)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
por: Shah, Nina, et al.
Publicado: (2020)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019)

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
por: Calderon, Moises A, et al.
Publicado: (2012)

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
por: Sullivan, Ryan J., et al.
Publicado: (2018)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

Neoadjuvant immunotherapy of locoregionally advanced solid tumors
por: Tarhini, Ahmad A, et al.
Publicado: (2022)

The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
por: Taube, Janis M, et al.
Publicado: (2020)

Allergen immunotherapy on the way to product-based evaluation—a WAO statement
por: Bachert, Claus, et al.
Publicado: (2015)

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
por: Quinn, Casey, et al.
Publicado: (2020)

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement
por: Tsimberidou, Apostolia M., et al.
Publicado: (2018)

Z-DNA enhances immunotherapy by triggering death of inflammatory cancer-associated fibroblasts
por: Herbert, Alan, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges
por: Rutella, Sergio, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges
por: Cesano, Alessandra, et al.
Publicado: (2020)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Publicado: (2021)

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ojkns13g67me5o3c70qfmnbiju